2021-2025 Retinal Drugs Market Advanced Features to Underscore Lucrative Growth Opportunities with Major Key Players – Teva, Bayer, Roche, Novartis, Regeneron, Merck, Shire

Global Retinal Drugs Market Synopsis:

The report covers a forecast and an analysis of the Retinal Drugs Market on a global and regional level. The study provides historical data for 2015, 2016, 2017 and 2018 along with a forecast from 2021 to 2025 based on revenue (USD Million) and volume (Kilotons). The study includes drivers and restraints of the Retinal Drugs Market along with the impact they have on the demand over the forecast period.

Some of the most important key factors driving the growth of the Global Retinal Drugs Market are increasing prevalence of retinal diseases and rapid growth in the number of cases of ophthalmic disorders due to age-related problems. Furthermore, development of several new products in forms of drug-releasing implants and biologics owing to the continuous efforts that are taken for the development and research of new treatment options are contributing to the market growth. The developments in the biologics-Lucentis-in the field of ophthalmology have completely shifted the treatment of the patients.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/273447 .

As per the regional analysis, North America is expected to account for a significant share of the market in terms of revenue. High research and development activities in the field of ophthalmic drugs, rising patient population, and high disposable income are factors which are attributed to the high market share of the region. Europe is expected to hold the second largest share of the market owing to rising incidence of retinal disorders, increasing awareness among people about treatment options, and growing prevalence of diabetes. APAC is expected to show a strong growth rate during the forecast period.

This report contains a complete product overview and its scope in the market to define the key terms and provide the clients a holistic idea of the market and its tendency. It comprehensively evaluates the Global Retinal Drugs Market with different perspectives for the purpose of providing a detailed, informative, and accurate analysis of regional growth, competition, market segmentation, and other important aspects.

Global Key Players:

1 Bayer

2 F. Hoffmann-La Roche

3 Novartis

4 Regeneron

5 Merck

6 Shire

7 Teva Pharmaceutical

8 ThromboGenics and More……………….

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Retinal Drugs Market Report 2021” @ https://www.businessindustryreports.com/buy-now/273447/single .

Product Type Segmentation

1 Wet AMD

2 Diabetic Retinopathy

3 DME

4 RVO

5 Mcnv

Industry Segmentation

1 Hospitals

2 Clinics

Latest Medical Industry News:

Teva Pharmaceutical (July 13, 2020) - Teva Announces Availability of ProAir Digihaler (albuterol sulfate 117 mcg) Inhalation Powder for Patients with Asthma and COPD - Teva Respiratory, LLC ., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. today announced the launch of ProAir Digihaler (albuterol sulfate 117 mcg) Inhalation Powder, the first and only digital rescue inhaler indicated in patients four years or older for the treatment or prevention of bronchospasm who have reversible obstructive airway disease, and for prevention of exercise-induced bronchospasm (EIB). The device features built-in Bluetooth Wireless Technology sensors, which connect to a companion mobile app and provide inhaler event information.

“The launch of ProAir Digihaler and its companion app provides a great opportunity for bringing a new digital health tool to asthma and COPD patients in the U.S.,” said Brendan O’Grady, Executive Vice President, North America Commercial at Teva Pharmaceuticals. “We are especially proud to provide our first Digihaler product at a time when digital health technology is growing and continues to transform patient care, since it will enable patients to electronically record and monitor their rescue inhaler use.”

The ProAir Digihaler inhaler detects, records and stores objective inhaler event data, including timestamp and inhalation characteristics such as peak inspiratory flow. Patients are then able to view this data on the ProAir Digihaler app, which informs patients if their inhaler technique may need improvement. If desired, patients can share these data with their healthcare providers (HCPs) to help facilitate dialogue around the assessment and management of their condition and discuss if their inhaler technique may need improvement.

“It is our belief that ProAir Digihaler and the companion app will help address an unmet need for HCPs by providing objective rescue inhaler use data when managing their patients,” said Sven Dethlefs , Executive Vice President, Global Marketing & Portfolio at Teva Pharmaceuticals . “Ultimately, this technology may help patients who use ProAir Digihaler and its accompanying app to have a better-informed dialogue with their HCP about their disease management and treatment decisions.”

ProAir Digihaler was approved by the U.S. Food and Drug Administration (FDA) in December 2018 and is a part of Teva’s Digihaler portfolio, which also includes AirDuo Digihaler (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir Digihaler (fluticasone propionate) Inhalation Powder. AirDuo Digihaler is indicated for the maintenance treatment of asthma in patients 12 years of age and older and ArmonAir Digihaler is indicated for the maintenance treatment of asthma in patients 12 years and older. Both products are expected to become commercially available to patients in the coming months. Please view the Important Safety Information for these products below.

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/273447 .

Major Points in Table of Contents:

Global Retinal Drugs Market Report 2021

1 Retinal Drugs Product Definition

2 Global Retinal Drugs Market Manufacturer Share and Market Overview

2.1 Global Manufacturer Retinal Drugs Shipments

2.2 Global Manufacturer Retinal Drugs Business Revenue

2.3 Global Retinal Drugs Market Overview

2.4 COVID-19 Impact on Retinal Drugs Industry

3 Manufacturer Retinal Drugs Business Introduction

3.1 Bayer Retinal Drugs Business Introduction

3.2 F. Hoffmann-La Roche Retinal Drugs Business Introduction

3.3 Novartis Retinal Drugs Business Introduction

3.4 Regeneron Retinal Drugs Business Introduction

3.5 Merck Retinal Drugs Business Introduction

3.6 Shire Retinal Drugs Business Introduction

About us

BusinessindustryReports.com is a digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that hold the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic, and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.